ReviewFrontiers in microbiology2016
Infection with and Carriage of Mycoplasma pneumoniae in Children.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 5 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio for predicting disease severity and outcomes in children with Mycoplasma pneumoniae pneumonia: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2024Pooled it
- A systematic review of the clinical features of pneumonia in children aged 5-9 years: Implications for guidelines and research.Journal of global health · 2022Pooled it
- Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.Emerging infectious diseases · 2020Pooled it
- Efficacy of glucocorticoids for the treatment of macrolide refractory mycoplasma pneumonia in children: meta-analysis of randomized controlled trials.BMC pulmonary medicine · 2019Pooled it
- Effect of montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia.The Journal of international medical research · 2019Trial
- Trial
- Innate and adaptive immunity pathways linking Mycoplasma pneumoniae to pediatric asthma phenotypes.European journal of pediatrics · 2026Review
- Post-pandemic resurgence of Mycoplasma pneumoniae and its emerging link with Rhinovirus in children.Infection · 2026Article
- E-cigarette/vaping associated lung injury: an ongoing public health crisis.BMJ case reports · 2026Article
- Risk factors associated with plastic bronchitis in children with severeJournal of thoracic disease · 2026Article
- Temporal dynamics of serum Mycoplasma pneumoniae antibodies in patients with acute respiratory infections: a large retrospective study.Annals of clinical microbiology and antimicrobials · 2026Article
- Comparison of severe and general Mycoplasma pneumoniae pneumonia in children: a targeted next-generation sequencing based study.BMC infectious diseases · 2026Article
- Population structure reveals clade- and region-specific dissemination of macrolide-resistantFrontiers in cellular and infection microbiology · 2026Article
- Genomic surveillance of the pneumonia outbreak caused byFrontiers in cellular and infection microbiology · 2026Article
- Comparative Analysis of Pathogen-Specific IgM Antibody and Nucleic Acid Detection in Patients with Respiratory Tract Infectionsin Northern Anhui, China: An Epidemiological Study.Infection and drug resistance · 2026Article
- Low-yield respiratory sequencing in pediatric upper respiratory specimens: a case series and reporting framework.Frontiers in pediatrics · 2026Article
- Cardiac Manifestations of Mycoplasma pneumoniae Infections: A Cohort Study 2007-2024.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- How to identify respiratory pathogens in primary health care - a review on the benefits, prospects and pitfalls in using point of care tests.Infection · 2025Review
- Epidemiology of severe acute respiratory infections in South Korea: a nationwide surveillance study.BMC pulmonary medicine · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
"Atypical" pneumonia was described as a distinct and mild form of community-acquired pneumonia (CAP) already before Mycoplasma pneumoniae had been discovered and recognized as its cause. M. pneumoniae is detected in CAP patients most frequently among school-aged children from 5 to 15 years of age, with a decline after adolescence and tapering off in adulthood. Detection rates by polymerase chain reaction (PCR) or serology in children with CAP admitted to the hospital amount 4-39%. Although the infection is generally mild and self-limiting, patients of every age can develop severe or extrapulmonary disease. Recent studies indicate that high rates of healthy children carry M. pneumoniae in the upper respiratory tract and that current diagnostic PCR or serology cannot discriminate between M. pneumoniae infection and carriage. Further, symptoms and radiologic features are not specific for M. pneumoniae infection. Thus, patients may be unnecessarily treated with antimicrobials against M. pneumoniae. Macrolides are the first-line antibiotics for this entity in children younger than 8 years of age. Overall macrolides are extensively used worldwide, and this has led to the emergence of macrolide-resistant M. pneumoniae, which may be associated with severe clinical features and more extrapulmonary complications. This review focuses on the characteristics of M. pneumoniae infections in children, and exemplifies that simple clinical decision rules may help identifying children at high risk for CAP due to M. pneumoniae. This may aid physicians in prescribing appropriate first-line antibiotics, since current diagnostic tests for M. pneumoniae infection are not reliably predictive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.